Summary:
A randomized, double-blind, placebo-controoled, parallel-group, multicenter study to explore changes in subcutaneous adipose tissue and modulation of skin inflammation after 12 weeks of treatment with secukinumab, compared to placebo, and up to 52 weeks of treatment with secukinumab in abult patients with moderate to severe plaque psoriasis.
Qualified Participants Must:
• Be 18 years or older and have at least 10% body surface area of psoriasis
Qualified Participants May Receive:
Study medication and visits at no cost as well as compensation for their time and travel.